Some AIDS Patients May Show Resistance To Sulfa Drugs

May 07, 1998

ANN ARBOR---Researchers in the University of Michigan HIV/AIDS Program and the U-M School of Public Health have discovered mutations in the genetic make-up of a type of pneumonia that is the most common severe opportunistic infection in people with AIDS.

The results are reported in the May 1998 issue of the journal AIDS.

The genetic mutations occurred in significantly larger numbers among patients who were taking medication that has proven very successful in preventing pneumocystis carinii pneumonia. The study's authors believe this could signal the emergence of resistance to these medications---called sulfa drugs. Sulfa has proven to be the most effective and widely used drug for preventing and treating pneumocystis, but it does fail in some cases.

"The importance of this study is that it documents mutations in pneumocystis in HIV/AIDS patients," says Powell Kazanjian, M.D., associate professor of internal medicine and director of the HIV/AIDS Program in the U-M Health System. "It is possible that the mutations may lead to resistance to sulfa in pneumocystis."

Kazanjian conducted the study in collaboration with Steven Meshnick, Ph.D., M.D., professor of epidemiology, U-M School of Public Health.

Researchers extracted DNA from the medical specimens of 27 patients who had been treated for pneumocystis between January 1991 and April 1997. Twenty of the patients had AIDS and the other seven were non-HIV-infected patients with compromised immune systems. Samples were obtained from the U-M, Indiana University Medical Center and Ann Arbor Veterans Administration Hospital.

Investigators examined the pneumocystis gene that is targeted by sulfa drugs and found a significantly higher incidence of mutation in patients who were taking sulfa drugs (71 percent) compared with those who weren't (15 percent). All of the mutations occurred in patients with AIDS.

The mutations occurred at two amino-acid positions. Kazanjian and Meshnick believe these two mutation points may be involved in sulfa binding. The same types of genetic mutations have been previously documented to be associated with resistance to sulfa in certain strains of meningitis, streptococcus and malaria.

The study authors say it was not possible to determine what caused the mutations or if the mutations represented actual resistance. Kazanjian and Meshnick are currently conducting a larger study to further investigate these findings. Follow-up studies to determine if resistance is occurring, Kazanjian says, will examine what effect larger sulfa doses have on these mutations, what is causing the mutations and exactly how the mutations might interfere with sulfa.

Kazanjian and Meshnick say study results indicate that the mutations are a recent occurrence. The research team found no evidence of mutations in any of the samples prior to 1995.

Sulfa targets pneumocystis at the genetic level, interrupting the synthesis of folic acid, which is responsible for cell division.
-end-


University of Michigan

Related Pneumonia Articles from Brightsurf:

Vaccine proves effective against the most severe type of pneumonia
A pneumococcal vaccine was effective at protecting children in Laos against the most severe type of pneumonia, a new study has found.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

Elderly patients with pneumonia twice as likely to die as those with broken hips, yet underestimate the danger of pneumonia
Elderly patients who are hospitalised with pneumonia are twice as likely to die as those hospitalised with hip fractures -- yet many elderly people fail to accurately assess their risk of pneumonia, concludes research due to be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

Pneumonia recovery reprograms immune cells of the lung
Researchers have determined that after lungs recover from infection, alveolar macrophages (immune cells that live in the lungs and help protect the lungs against infection) are different in multiple ways and those differences persist indefinitely.

Skin and mucous membrane lesions as complication of pneumonia
Painful inflammatory lesions of the skin and mucous membranes may occur in children who develop bacterial pneumonia.

Vaccine reduces likelihood of severe pneumonia
A new study has found severe pneumonia decreases by 35 per cent in children who receive a vaccine against a pneumonia-causing bacteria.

Bacteria in pneumonia attack using bleaching agent
Research shows that bacteria use hydrogen peroxide to weaken the immune system and cause pneumonia.

Many kids with pneumonia get unnecessary antibiotics, chest X-rays
Preschool children with community-acquired pneumonia often receive unnecessary tests and treatment at outpatient clinics and emergency departments, according to a nationally representative study led by Todd Florin, M.D., MSCE, from Ann & Robert H.

Certain psychiatric drugs linked with elevated pneumonia risk
A review of published studies indicates that use of benzodiazepines and benzodiazepine related drugs (BZRDs), which are prescribed to treat various psychiatric diseases, may increase the risk of pneumonia.

Bacterial pneumonia far more dangerous to the heart than viral pneumonia, study finds
Heart complications in patients diagnosed with bacterial pneumonia are more serious than in patients diagnosed with viral pneumonia, according to new research.

Read More: Pneumonia News and Pneumonia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.